Discussion
The U.S. Food and Drug Administration (FDA) has agreed to review uniQure’s application seeking accelerated approval of AMT-130, a gene therapy candidate for Huntington’s disease that is now called ifezuntirgene inilparvovec. “The FDA’s acceptance of our [application] for review marks an important milestone for the Huntington’s disease community,”…